Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





New Diagnostic Device Identifies COVID-19 Patients at Risk of Potentially Lethal Cytokine Storm

By LabMedica International staff writers
Posted on 19 Feb 2021
Researchers have developed a diagnostic device, called an Immuno-storm chip, that could identify which cancer and COVID-19 patients are at risk of a potentially lethal ‘cytokine storm’.

The device was invented by scientists from the Australian Institute for Bioengineering and Nanotechnology (AIBN) at The University of Queensland (Queensland, Australia) and could help healthcare workers triage and closely monitor high risk patients and to begin treatment much earlier.

Cytokines are small proteins that act as messengers between cells in the immune system. More...
They play a critical role in triggering inflammation by stimulating the movement of immune cells toward sites of injury or infection. However, if the release of cytokines becomes uncontrolled, this causes hyperinflammation which damages tissue. This, in turn, causes more cytokines to be released in a vicious, potentially lethal cycle called a ‘cytokine storm’. Cytokine storms can arise during a variety of diseases, as well as in response to immune-therapies. Unfortunately, it’s very difficult to predict who will develop a cytokine storm. Until recently, they were thought to arise very suddenly, but there is now evidence that a very faint but distinctive pattern of cytokines begins to emerge several days before the full-blown storm.

Scientists at the AIBN have developed a nanotechnology device, called an Immuno-storm chip, that can detect this early warning signal on a miniaturized platform with minimal sample. They designed a nanoscale array of gold pillars to which they attached antibodies that stick to specific cytokines in blood. If these cytokines are present in a blood sample as small as a single drop, they will bind to the gold ‘nanopillars’. These captured cytokines are then detected by gold-silver ‘nanotag’ particles. The team designed these nanotags to emit light whenever they encounter a cytokine. The chip’s small size - about the size of a SIM card - meant the diagnostic technology could eventually be made relatively portable.

“Whether in a cancer treatment setting or when monitoring infectious diseases such as acute COVID-19, long-haul COVID-19 and sepsis, the Immuno-storm chip could provide critical medical information that guides important clinical decisions. Critically, it could inform doctors to begin, or to ease off treatments, by accurately monitoring the patient’s immune response before it goes crazy,” said Professor Matt Trau, a researcher AIBN. “Detection of the detailed cytokine signature for vulnerable COVID-19 patients with the Immuno-storm chip could also be used to personalize the therapy of these patients, tuned in to alleviate their specific excessive immune system response.”

Related Links:
The University of Queensland


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Automated Urinalysis Solution
UN-9000
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The method combines ultrasonic and fluorescence techniques to track amyloid aggregation in real time (Image Credit: Shutterstock)

Blood Test Measures Amyloid Seeding Activity to Detect Alzheimer’s Disease

Early, accurate diagnosis of Alzheimer’s disease (AD) remains challenging in routine practice, despite its role as the leading cause of dementia worldwide. Confirmation typically relies on cerebrospinal... Read more

Pathology

view channel
Image: TRUECAM automatically eliminates ambiguous or uninformative regions in whole-slide pathology images, enhancing the reliability of diagnostic analysis. (Photo courtesy of PolyU)

AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis

Ensuring reliable cancer diagnosis from digital pathology remains a critical challenge as clinical decisions rely on accurate slide interpretation. While artificial intelligence (AI) has accelerated whole-slide... Read more

Industry

view channel
Image: HealthTab will distribute the Abbott Afinion 2 Analyzer to NHS-linked pharmacies for hemoglobin A1c (HbA1c) and lipid profile testing. (Photo courtesy of Abbott)

New Collaboration Expands Point-of-Care Testing Across UK Community Pharmacies

HealthTab, a wholly owned subsidiary of Avricore Health, has entered a formal collaboration agreement with Abbott to supply and distribute Abbott’s point-of-care testing products in the UK through the... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.